Pyrethroid Drug Class List

Drugs in Drug Class: Pyrethroid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs	PERMETHRIN	permethrin	CREAM;TOPICAL	074806-001	Jan 23, 1998	AB	RX	No	No
Padagis Israel	PERMETHRIN	permethrin	CREAM;TOPICAL	076369-001	Apr 21, 2003	AB	RX	No	Yes
Encube Ethicals	PERMETHRIN	permethrin	CREAM;TOPICAL	211303-001	Apr 3, 2019	AB	RX	No	No

Pyrethroid Market Analysis and Financial Projection

Last updated: April 25, 2026

Pyrethroid Drugs: Market Dynamics and Patent Landscape

What is the pyrethroid drug market structure?

Pyrethroids are insecticides, not human therapeutics. As a result, the “pyrethroid drug” market in most jurisdictions is an agrochemical and public-health biocide market, not a pharmaceutical market with R&D pipelines, clinical trials, and payer-driven formularies.

Market dynamics are dominated by:

• Regulatory-driven reformulation (risk mitigation, impurity limits, and environmental fate controls)
• Patent and exclusivity over active ingredients (initial discoveries and downstream process/combination protection)
• Generic and technical-grade substitution once ingredient patents expire
• Registration maintenance costs that slow market exit and shape competitive intensity

From an investment and licensing perspective, the competitive battleground is typically active ingredient ownership, intermediate/process IP, and end-use product registrations tied to local approvals and label claims.

---

How do patents and exclusivities govern pyrethroid supply?

Pyrethroid intellectual property is typically structured along three layers:

1. Core molecule patents (composition of matter)
   • Cover the pyrethroid active ingredient (or key stereoisomers, when applicable).
2. Process patents
   • Cover synthesis routes, intermediates, catalysts, and improved yields.
3. Formulation and use patents
   • Cover combinations, adjuvants, controlled-release formulations, and specific end-use methods.

Because many pyrethroids were developed earlier (multiple generations since the 1970s to 1990s), much of the market now sits in a post-primary patent environment for many widely used molecules. Competitive advantage shifts toward:

• cost of goods (manufacturing and impurities management)
• registration economics
• brand and channel relationships
• local-compliance product performance

---

Which pyrethroids anchor the patent landscape today?

The “pyrethroid” class includes multiple active ingredients. Patent status varies by molecule and jurisdiction, but the landscape is broadly shaped by expiries of foundational patents and ongoing secondary filings.

Common major-use pyrethroids in global markets include:

• Permethrin
• Cypermethrin
• Deltamethrin
• Lambda-cyhalothrin
• Esfenvalerate
• Fenpropathrin
• Tefluthrin
• Bifenthrin
• Fluvalinate
• Tralomethrin
• Zeta-cypermethrin
• Triflumuron is not a pyrethroid (included here only to avoid conflation; it is an insect growth regulator, not a pyrethroid)

For a precise, molecule-by-molecule patent map, you need per-jurisdiction legal status (INPADOC/PAIR equivalents) and priority/expiration chains. With only the class-level scope provided, a complete and accurate legal-status chart cannot be produced.

---

What market drivers determine pricing and volume for pyrethroids?

1) Regulatory constraints drive portfolio churn

Pyrethroid products live under pesticide and biocide regulation. Label approvals, maximum residue limits (where applicable), and environmental hazard assessments influence:

• which actives remain commercially viable
• whether new formulations can be marketed under existing registrations
• how manufacturers respond to risk assessments (e.g., impurity limits, solvent systems, application rates)

This pushes companies into reformulation and stewardship spend even after core patents expire.

2) Replacement dynamics accelerate after technical disclosures

Once a pyrethroid active becomes widely produced and technical-grade supply consolidates, price tends to compress. Companies compete on:

• manufacturing cost
• compliance grades (impurity profile)
• formulation performance under local pest-control programs

3) Public-health and vector-control procurement behaves differently

Vector-control tenders often prioritize:

• speed of deployment
• adherence to recommended regimens
• quality and stability in formulations This can delay purely price-only competition, because procurement favors supply certainty and technical support.

---

What does the patent landscape imply for new entry?

For most pyrethroids, new entrants face two realities:

1. Primary molecule patents are largely legacy
   • Most foundational actives are well beyond typical 20-year filing windows.
2. Secondary IP and registration create barriers
   • Process improvements, impurity control, and formulation IP can remain valuable even after active ingredient expiries.
   • Regulatory registration and data packages create a cost wall that is often more binding than patent text for launch timing.

Where companies can still create defendable IP advantage, it is commonly through:

• stereochemical refinement (when not already exhausted)
• specific manufacturing improvements tied to impurity reduction
• combination products with distinct label claims
• controlled-release or synergist-enabled formulations

---

How do you evaluate freedom-to-operate (FTO) in pyrethroids?

A robust FTO workflow for pyrethroid actives and products should evaluate:

• composition claims for the active ingredient (and any stereoisomer or isomer ratio claims)
• process claims that cover your manufacturing route and key intermediates
• formulation claims for the commercial product (solvent system, carriers, and additives)
• combination/use claims tied to a specific pest or application method

Because pyrethroid products are distributed as formulations, many disputes arise from:

• ingredient identity and isomer ratio
• impurity profiles (and whether a “same active” process violates a protected impurity specification)
• combination claims in finished products

Without per-molecule and per-country legal status data, any litigation-ready FTO conclusion would be speculative.

---

Key Takeaways

• Pyrethroids are insecticides and biocides, so the “drug” market framing aligns more closely with agrochemical/biocide patenting and registration than with pharmaceutical clinical-development exclusivities.
• Market competition is shaped by regulatory reformulation and registration maintenance economics, not only by active-ingredient patent expiry.
• The pyrethroid patent landscape typically stacks molecule patents, process patents, and formulation/use patents; after primary expiries, secondary IP plus registration are the main remaining barriers.
• A complete patent landscape for the class requires molecule-specific and jurisdiction-specific legal status; class-level inputs are insufficient for accurate expiry and claim mapping.

---

FAQs

1) Are pyrethroids treated like pharmaceutical drugs in patent analytics?

No. They are regulated and commercialized as pesticides/biocides. The patent and exclusivity logic is centered on agrochemical active ingredients and product registrations.

2) What usually survives after primary pyrethroid patents expire?

Process and formulation IP, plus combination/use claims, often retain value. Registration and regulatory maintenance costs also remain structurally important.

3) What are the main sources of competitive differentiation?

Manufacturing cost, compliance and impurity profiles, formulation performance, label approvals, and supply reliability for end-use programs.

4) Why does FTO often matter for “the same active ingredient”?

Because patents can protect processes, stereoisomer ratios, impurity control, and finished-product formulations, even when the molecule name matches.

5) What is the most practical unit of analysis for pyrethroid patent work?

A single active ingredient (plus isomer definition where relevant), in each target jurisdiction, mapped to composition, process, and formulation claim families.

---

References

[1] OECD. (n.d.). Guidelines for the testing of chemicals: Pesticides and biocides regulatory context. Organisation for Economic Co-operation and Development.
[2] U.S. Environmental Protection Agency (EPA). (n.d.). Pesticides registration and regulatory framework.
[3] European Chemicals Agency (ECHA). (n.d.). Biocides and pesticide-related regulatory information.